FIGURE 2 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers

Sensitivity of NSCLC cell lines to erlotinib and alisertib. A, Western blot images and quantification of the protein levels of EGFR and AURKA in NSCLC cell lines and the human fibroblast cell line FC1010. Data for NSCLC cell lines are normalized to the levels in FC1010 cells. B, Determination of AURKA gene copy number in NSCLC cell lines, using the colorectal cancer cell lines HCT116 and SW420 as standards. Normalization to RNAseP, blue, or ALB, orange. The slopes of the standard curves were −3.64 (AURKA), −3,46 (RNAseP), −3.49 (ALB). Determination of sensitivity of the NSCLC cell lines and FC1010 control to erlotinib (C) and alisertib (D), with quantified IC₅₀ values (E), based on CelltiterBlue analysis of viability after growth with indicated drugs for 72 hours. N/A, IC₅₀s were not calculated because of low sensitivity to the drug. F, Combination indexes for erlotinib and alisertib over a range of molar ratios. Results shown reflect averages from four to five independent experiments, each done in quadruplicate, ± SEM and were calculated using CompuSyn software.